HuniLife Biotechnology
HuniLife Biotechnology, Inc. is a Taiwan-based biopharmaceutical company founded in 2013, dedicated to developing efficacious therapeutics for human diseases, especially in the fields of cancer and immune diseases. The company focuses on early-stage drug development, clinical trials, and has a pipeline of innovative drugs with global patent protection. It aims to improve human health and become a leading international biotech company.
Industries
Nr. of Employees
small (1-50)
HuniLife Biotechnology
114 Taipei City, Neihu District, Neihu Road, Section 1, No. 308, 6th Floor, Taiwan
Products
ENO1-targeting monoclonal antibody (clinical programs for fibrotic and immune indications)
Humanized monoclonal antibody that blocks ENO1-mediated plasmin activation and associated pathological glycolysis; developed for indications including idiopathic pulmonary fibrosis and multiple sclerosis with completed Phase I healthy volunteer studies and ongoing patient studies.
ENO1-based antibody–drug conjugates (ADC)
Preclinical ADC programs that conjugate immunosuppressive or cytotoxic payloads to ENO1-targeting antibodies to selectively deliver payloads to ENO1-expressing inflammatory or cancer cells.
ENO1-directed adoptive cell therapy (preclinical)
Immune cell product concept that equips patient-derived immune cells with ENO1-specific recognition to target and kill ENO1-expressing tumor cells after autologous transfer.
Nanomicelle-based drug delivery integration (nanoparticle carrier)
Co-development and integration of a nanomicelle drug delivery platform for enhanced tumor drug delivery and reduced systemic toxicity (technology transfer reported).
ENO1-targeting monoclonal antibody (clinical programs for fibrotic and immune indications)
Humanized monoclonal antibody that blocks ENO1-mediated plasmin activation and associated pathological glycolysis; developed for indications including idiopathic pulmonary fibrosis and multiple sclerosis with completed Phase I healthy volunteer studies and ongoing patient studies.
ENO1-based antibody–drug conjugates (ADC)
Preclinical ADC programs that conjugate immunosuppressive or cytotoxic payloads to ENO1-targeting antibodies to selectively deliver payloads to ENO1-expressing inflammatory or cancer cells.
ENO1-directed adoptive cell therapy (preclinical)
Immune cell product concept that equips patient-derived immune cells with ENO1-specific recognition to target and kill ENO1-expressing tumor cells after autologous transfer.
Nanomicelle-based drug delivery integration (nanoparticle carrier)
Co-development and integration of a nanomicelle drug delivery platform for enhanced tumor drug delivery and reduced systemic toxicity (technology transfer reported).
Services
Comprehensive preclinical package including mechanism studies, in vivo efficacy models and toxicology to support IND filings.
Execution and management of Phase I and early patient studies including healthy volunteer studies, safety/tolerability assessments and patient recruitment for targeted indications.
Negotiation and management of in‑licensing, out‑licensing and co‑development agreements for proprietary technologies and candidate drugs.
Translational study design, data generation and scientific communication to support development decisions and peer-reviewed publication.
Comprehensive preclinical package including mechanism studies, in vivo efficacy models and toxicology to support IND filings.
Execution and management of Phase I and early patient studies including healthy volunteer studies, safety/tolerability assessments and patient recruitment for targeted indications.
Negotiation and management of in‑licensing, out‑licensing and co‑development agreements for proprietary technologies and candidate drugs.
Translational study design, data generation and scientific communication to support development decisions and peer-reviewed publication.
Expertise Areas
- Therapeutic monoclonal antibody development
- Antibody–drug conjugate (ADC) development
- Adoptive cell therapy for oncology
- Preclinical efficacy and translational research
Key Technologies
- Monoclonal antibody therapeutics
- Antibody–drug conjugates (ADCs)
- Immune cell engineering / adoptive cell therapy
- Nanomicelle-based drug delivery
News & Updates
On August 19, 2024, HuniLife published research on ENO1 multiple myeloma antibody in Oncology Reports.
On August 24, 2022, HuniLife's ENO1 prostate cancer antibody was published in an international journal, with plans to start clinical trials in 2023.
On August 23, 2022, HuniLife's ENO1 prostate cancer antibody was published in an international journal, with plans to start clinical trials in 2023.
On July 20, 2018, HuniLife's ENO1 antibody HuL001 received the Taipei Biotechnology Award for technology transfer.
In October 2015, HuniLife successfully transferred the ENO1 antibody patent technology from NHRI and DCB for cancer and immune disease treatment.
HuniLife focuses on early-stage research, clinical trials, and development of first-in-class therapeutics targeting ENO1 for cancer and immune diseases.
On August 19, 2024, HuniLife published research on ENO1 multiple myeloma antibody in Oncology Reports.
On August 24, 2022, HuniLife's ENO1 prostate cancer antibody was published in an international journal, with plans to start clinical trials in 2023.
On August 23, 2022, HuniLife's ENO1 prostate cancer antibody was published in an international journal, with plans to start clinical trials in 2023.
On July 20, 2018, HuniLife's ENO1 antibody HuL001 received the Taipei Biotechnology Award for technology transfer.
In October 2015, HuniLife successfully transferred the ENO1 antibody patent technology from NHRI and DCB for cancer and immune disease treatment.
HuniLife focuses on early-stage research, clinical trials, and development of first-in-class therapeutics targeting ENO1 for cancer and immune diseases.